Laboratory research

Our Partners

ORIGIN brings together a highly multidisciplinary consortium of leaders in their respective fields (academia and industry with photonics, engineering, medical physics, radiobiology, and clinical expertise), in order to develop a new 16 point array optical fibre dosimeter for both LDR- and HDR-BT, with novel algorithms to provide 3D dose imaging with source localisation capability. The involvement on both industry and clinical partners from the outset will ensure that patient care is at the forefront across the entire value chain. The integration of the ORIGIN system within existing clinical treatment planning systems and after-loader delivery devices will provide enhanced adaptive therapy, for improved patient outcomes.
Life science research

ORIGIN

Partners role

UL

Coordinator Development and integration of optical fibre LDR-BT dosimeter. Software development for dose imaging and source localisation.

DV

Development and integration of optical fibre HDR-BT dosimeter

UNINS

Development of the photon detector array for optical signal control and acquisition

VUB

Redesign of the LDR- and HDR-BT probes for improved optical performance and compliance with spatial resolution requirements; prototype fabrication and demonstration of repeatable high-volume manufacturability

EZB

System integration with existing clinical BT delivery devices and advise on regulation and marketability

QUB

End-user. system requirements, validation of the optical fibre based dose imaging and source localisation systems and protocol development. Development of semi-anatomical phantoms.

GC

End-user. system requirements, validation of the optical fibre LDR-BT dose imaging and source localisation systems and protocol development

CAL

End-user. system requirements, validation of the optical fibre HDR-BT dose imaging and source localisation systems and protocol development

ORIGIN

Our Partners

UL-LOGO

University of Limerick (UL)

www.ul.ie

The University of Limerick (UL) with over 13,000 students and 1,300 staff is an energetic and enterprising institution with a proud record of innovation and excellence in education, research and scholarship. The dynamic, entrepreneurial values which drive UL’s mission and strategy ensure that we capitalise on local, national and international engagement and connectivity.

Research at UL is renowned for its close alignment to real world problems and the university has an enviable reputation in fundamental research, which can have real impact on society and the economy alike. This strong focus allowed UL to gain a five star rating for innovation and excellence from QS, the international ranking body. This close alignment has also allowed UL to successfully compete for and win the right to host 5 national centres of excellence, all of whom have significant industry involvement, and aim to tackle real world issues. UL has a strong international reach and Involvement in the European Framework actions from FP2 to FP7, and current involvement in Horizon 2020 has grown UL’s international network of collaborators.

The project will be hosted by Optical Fibre Sensors Research Centre (OFSRC), one of nine research centres within the Electronic & Computer Engineering Department, College of Science and Engineering. Established in 1997 by Director Prof. Elfed Lewis, the OFSRC has been engaged in numerous national, European funded and industry collaborative projects in the general area of optical sensors for environmental, medical and industrial process monitoring. The Optical Fibre Sensors Research Centre currently occupies a laboratory which is 75m2 in area and has extensive optical test and calibration equipment including fusion splicer, optical attenuation test, OTDR, spectrometer, and stabilised sources.

VUE

Vrije Universiteit Brussel (VUB)

www.vub.be

Vrije Universiteit Brussel (VUB) belongs to the UNICA Network of Universities of the Capitals of Europe. In ORIGIN, VUB is represented by Brussels Photonics (B-PHOT), which is a research and innovation group within the Faculty of Engineering of VUB. VUB B-PHOT’s staff consists of a total of 59 collaborators, whose photonic R&I activities are coordinated by Prof. Hugo Thienpont. VUB B-PHOT is internationally recognized for its fundamental, strategic and applied research in the field of photonics and is also uniquely involved in industry-related photonics innovation projects in the Flanders Region and Europe. VUB B-PHOT has more than 30 years of experience in photonics-enabled research and more than 20 years in photonics-enabled innovation. Today VUB B-PHOT focuses its research and innovation actions on six topical areas: freeform optical systems, optical fiber sensing, photonic-enhanced lab-on-chip, optical spectroscopy, semiconductor lasers, and nonlinear photonic integrated circuits. VUB B-PHOT’s advanced in-house technology, metrology, and demonstrator platforms for the fabrication, testing, and replication of plastic and glass optical components, wafer-scale lab-on-chips, and optical fiber-sensors are accessible to national and international collaborative research groups for interdisciplinary research and innovation in the topical areas of e.g. food-safety, biotechnology, advanced manufacturing, textile, secure data communication, archaeometry, and many more. VUB B-PHOT strongly collaborates with companies in photonics-enabled innovation projects that span a variety of industrial sectors such as high-end projectors and displays, food-sorting, digital printing, automotive, manufacturing industry, datacom; and lighting. Since 2007 the VUB B-PHOT team has the “Methusalem” label of research excellence and “Spearhead for Industrial Valorization” special status, both awarded by the Flemish government for its excellent track record in fundamental and applied research, and its outstanding industrial research validation, knowledge transfer, and entrepreneurship respectively.
dose-vue

DoseVue N.V.

www.dosevue.com

DoseVue NV, a spin-off company of the Belgian Nuclear Research Center, is an ISO 13485:2016 certified company. The company is primarily active in the field of cancer radiotherapy. The goal of its products is to allow systematic and accurate dose monitoring in tumors and organs at risk. DoseVue already brought a first product to the market, for research purposes. This device allows to monitor radiation in different kind of preclinical and/or industry related application. The company is experienced in working in small or big consortia and in currently part of several research projects. DoseVue is currently collaborating with several hospitals, across Europe.
queens

Queen’s University Belfast (QUB)

www.qub.ac.uk

Queen’s University Belfast (QUB) is a member of the Russell Group of the top 24 research active universities in the UK and has over 25,000 full and part time students. The Centre for Cancer Research & Cell Biology (CCRCB) is part of the School of Medicine, Dentistry and Biomedical Sciences of Queen’s University Belfast. It is a cross faculty and multi-disciplinary centre with over 300 clinical and basic researchers working in cancer and cell biology related areas from basic research through to translational and clinical application with a focus on personalised cancer medicine. It has a strong background in mechanistic studies of new targeted agents, through translational and clinical projects. It is closely aligned to the Northern Ireland Clinical Cancer Centre situated on the same campus and also has strong collaborative links with researchers in the school of Pharmacy, Physics and Biological Sciences. Radiation Science is a key focus area of the Centre bringing together multidisciplinary strengths in Radiation Physics, Biology and Oncology focused on clinical advances in radiotherapy including research on radiation risk. This is delivered through an Advanced Radiotherapy Group consisting of radiation biologists, radiotherapy physicists and radiation oncologists.

Ant

Centre Antoine-LACASSAGNE (CAL)

www.centreantoinelacassagne.org

The Antoine Lacassagne Center (Centre Antoine-LACASSAGNE – CAL) is a French anti-cancer center involved in UNICANCER. Established in 1961, it provides care missions (5500 patients per year) and research. The CAL includes several departments: medical oncology, radiotherapy, imaging, surgical oncology, laboratories etc.

The external radiotherapy department is equipped with several treatment devices offering a large choice for patient care. The platform includes:

  • 2 LINAC Accelerators (VARIAN)
  • 2 Tomotherapy accelerators (ACCURAY)
  • 1 CyberKnife accelerator (ACCURAY)
  • 2 Contactherapy
  • 1 afterloader High Dose Rate (Eckert & Ziegler BEBIG))
  • 1 cyclotron low energy (MEDYCIC)
  • 1 S2C2 ProteusOne high energy (IBA)

 

There is a direct link between this project and our institute. Indeed, we are practicing high-dose rate (HDR) and low-dose rate (LDR) brachytherapy in clinical routines since many years. We are currently treating a variety of location and cancer types using HDR (prostate, cervix, breast, Head & Neck), it administers 5-10 patients weekly. Concerning the LDR, we are doing prostate implantation of Iodine 125), it administers 2 patients monthly.

This project provides a great opportunity to develop and implement an in vivo dosimetry system using the optical fiber technology to ensure delivery of the appropriate treatment dose. This platform will give us the opportunity to share our clinical expertise with our collaborators.

To evaluate the response of this new system, several measurements will be made on phantom. Other detectors or Monte-Carlo simulations may be used to validate these measures in clinically relevant conditions.

eck

Eckert & Ziegler BEBIG (EZB)

www.bebig.com

Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the healthcare industry with a very strong focus on brachytherapy. Its core business is the production and distribution of medical products for the treat¬ment of cancer, using HDR, LDR and x-ray brachytherapy. The company’s headquarters and production facilities are in Germany and the USA, with subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company’s products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists. Eckert & Ziegler BEBIG employs approximately 145 people.

Eckert & Ziegler BEBIG has partnered with the company PTW to provide in-vivo dosimetry solution in HDR brachytherapy including the hardware and software integration in the HDR afterloader device. Hence, Eckert & Ziegler BEBIG has commercial and technical expertise in integrating in-vivo dosimetry solution and a commercial interest to market the solution.

degli

Università degli Studi dell’Insubria (UNINS)

www.uninsubria.it

Università degli Studi dell’Insubria, established in 1998, is a research oriented institution based in Varese and Como, in the northern part of Italy. Varese hosts the faculties of Economics, Medical Science, Biology/Biotechnology, Civil Engineering and Computer Science while the hard core science (Chemistry, Physics and Mathematics), Environmental science and the School of Law are located in Como.

 

By the time of writing, about 12 000 students at undergraduate and master level are enrolled at UNINS and the graduate school offers courses & research activities in the major fields to about 150 Ph.D. candidates, the majority of which are financially benefitting from scholarships by the University.

 

The scientific person in charge for the ORIGIN project is part of the Department of Science and High Technology, house of Chemists, Physicists and Mathematicians. The Dept. has a long standing tradition in participating and leading EU funded projects in different domains since the Framework Program 5; projects in cooperation with national and international companies are also key to the activities of the research staff at the Dept.

logo-galway

Galway Clinic (GC)

www.galwayclinic.com

The Galway Clinic is a state of the art hospital which provides 24 hour health care services. There are in excess of 120 Physicians and Surgeons who have admitting and operating privileges and some have Consultant Suites within the Clinic. The Clinic has an occupancy rate of 95% and an average length of stay of 3.6 days. It has 146 in-patient beds; eight of which are ICU beds and the remaining 138 are on five in-patient units (Mother Teresa Unit, O’Malley Unit, Freyer Unit, John Paul II Unit and Our Lady of Knock Unit). There is a Same Day Surgery unit and Emergency Room. There are seven operating suites, an endoscopy suite, a catheterisation laboratory and an oncology day unit. Diagnostic modalities include CT, PET/CT, and MRI among others. The project will be hosted by the Department of Medical Physics at the Galway Clinic.